1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phospho-D-myo-inositol

Metabolite details

Identifier

BSNJSZUDOMPYIR-CUKLWHKZSA-N

InChI Key

BSNJSZUDOMPYIR-CUKLWHKZSA-N

IUPAC name

(2R)-3-(hexadecanoyloxy)-1-[(hydroxy{[(1S,2R,3R,4S,5S,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxy}phosphoryl)oxy]propan-2-yl (9Z,12Z)-octadeca-9,12-dienoate

Preferred name

1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phospho-D-myo-inositol

INN name

—

Synonym

PI(16:0/18:2ω6)

ChEBI

CHEBI:73212

Reactome pathways

• No Reactome pathways listed for this metabolite.

Observed in studies

• Large-Scale Plasma Analysis Revealed New Mechanisms and Molecules Associated with the Host Response to SARS-CoV-2.
• Metabolomics and lipidomics reveal perturbation of sphingolipid metabolism by a novel anti-trypanosomal 3-(oxazolo[4,5-b]pyridine-2-yl)anilide
• Distinct succinate modifying products are clinically diagnostic and prognostic biomarkers for fumarate hydratase deficient renal cell carcinoma
• Global Analyses of Selective Insulin Resistance in Hepatocytes due to Palmitate Lipotoxicity

Observed in differential profiles

• non_COVID_19_healthy_vs_non_critical_COVID_19
• Control_vs_OXPA_Treatment
• Control_vs_OXPA_Treatment
• Normal_control_no_tumor_vs_FH_deficient_RCC
• Control_vs_Palmitate